JP7017410B2 - ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤 - Google Patents

ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤 Download PDF

Info

Publication number
JP7017410B2
JP7017410B2 JP2017538686A JP2017538686A JP7017410B2 JP 7017410 B2 JP7017410 B2 JP 7017410B2 JP 2017538686 A JP2017538686 A JP 2017538686A JP 2017538686 A JP2017538686 A JP 2017538686A JP 7017410 B2 JP7017410 B2 JP 7017410B2
Authority
JP
Japan
Prior art keywords
compound according
item
quencher
alkyl
label
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017538686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511556A (ja
JP2018511556A5 (enExample
Inventor
マシュー エス． ボギョ，
マーティン バードース，
レスリー オホリ，
ニマリ ピー． ウィットハナ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2018511556A publication Critical patent/JP2018511556A/ja
Publication of JP2018511556A5 publication Critical patent/JP2018511556A5/ja
Priority to JP2022010930A priority Critical patent/JP2022044770A/ja
Application granted granted Critical
Publication of JP7017410B2 publication Critical patent/JP7017410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017538686A 2015-01-22 2016-01-22 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤 Active JP7017410B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022010930A JP2022044770A (ja) 2015-01-22 2022-01-27 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106400P 2015-01-22 2015-01-22
US62/106,400 2015-01-22
PCT/US2016/014606 WO2016118910A1 (en) 2015-01-22 2016-01-22 Protease-activated contrast agents for in vivo imaging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022010930A Division JP2022044770A (ja) 2015-01-22 2022-01-27 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤

Publications (3)

Publication Number Publication Date
JP2018511556A JP2018511556A (ja) 2018-04-26
JP2018511556A5 JP2018511556A5 (enExample) 2019-03-07
JP7017410B2 true JP7017410B2 (ja) 2022-02-08

Family

ID=56417841

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017538686A Active JP7017410B2 (ja) 2015-01-22 2016-01-22 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤
JP2022010930A Pending JP2022044770A (ja) 2015-01-22 2022-01-27 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022010930A Pending JP2022044770A (ja) 2015-01-22 2022-01-27 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤

Country Status (6)

Country Link
US (3) US10570173B2 (enExample)
EP (1) EP3247802B1 (enExample)
JP (2) JP7017410B2 (enExample)
KR (1) KR102668593B1 (enExample)
CN (1) CN107406872B (enExample)
WO (1) WO2016118910A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406872B (zh) * 2015-01-22 2023-03-28 里兰斯坦福初级大学理事会 用于标记动物组织的化合物、组合物及其应用
GB201617935D0 (en) 2016-10-24 2016-12-07 Queens University Of Belfast The Binding compound and uses thereof
EP3510380B1 (en) 2016-12-23 2023-11-08 The Board of Trustees of the Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
EP3601261A4 (en) * 2017-03-30 2021-07-14 The Board of Trustees of the Leland Stanford Junior University CONTRAST AGENTS ACTIVATED BY A PROTEASE FOR IN VIVO IMAGING
US20220105206A1 (en) * 2020-10-02 2022-04-07 Board Of Regents, The University Of Texas System Sensitivity advances in ultrasound switchable fluorescence systems and techniques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535167A (ja) 2007-08-03 2010-11-18 サノフィ−アベンティス カスパーゼイメージングプローブ
JP2012508233A (ja) 2008-11-07 2012-04-05 チルドレンズ ホスピタル メディカル センター 膜貫通薬物送達システムへの適用のためのサポシンｃ、並びに関連のタンパク質及びペプチドの融合性
JP2014111600A (ja) 2006-04-28 2014-06-19 Childrens Hospital Medical Center 膜貫通薬物送達システムに適用するためのプロサポシン由来の融合タンパク質又はポリペプチドを含む組成物
WO2014145257A2 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60888A (en) * 1978-06-16 1984-07-31 Yeda Res & Dev Substrates and process for the quantitative assay of enzymes
AU2704395A (en) 1995-06-13 1997-01-09 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative di seases
US7303741B2 (en) 2002-09-23 2007-12-04 General Electric Company Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism
US8133482B2 (en) * 2003-11-14 2012-03-13 The Trustees Of The University Of Pennsylvania Activatable photodynamic therapy agents
US20060148014A1 (en) * 2004-12-09 2006-07-06 Sergei Agoulnik Tubulin isotype screening in cancer therapy using hemiasterlin analogs
US8968700B2 (en) 2005-08-11 2015-03-03 The Board Of Trustees Of The Leland Stanford Junior University Imaging of protease activity in live cells using activity based probes
CN101652149B (zh) * 2007-02-28 2012-11-14 塞诺菲-安万特股份有限公司 成像探针
MY162041A (en) 2007-02-28 2017-05-31 Sanofi Aventis Imaging probes
WO2008139206A2 (en) * 2007-05-16 2008-11-20 Ge Healthcare As Optical imaging agents
WO2009124265A1 (en) 2008-04-03 2009-10-08 The Board Of Trustees Of The Leland Stanford Junior University Probes for in vivo targeting of active cysteine proteases
BRPI0917478A8 (pt) * 2008-08-06 2017-05-23 Univ Leland Stanford Junior uso de beta-lactamase bacteriana para diagnóstico in vitroe geração de imagem, diagnóstico e terapêutica in vivo
US9155471B2 (en) * 2009-05-27 2015-10-13 Lumicell, Inc'. Methods and systems for spatially identifying abnormal cells
WO2012021800A2 (en) 2010-08-13 2012-02-16 Banyan Biomarkers Caspase inhibitors as therapeutics for neural and organ injury and imaging
WO2012118715A2 (en) 2011-02-28 2012-09-07 The Board Of Trustees Of Leland Stanford Junior University Non-peptidic quenched fluorescent imaging probes
US8709830B2 (en) * 2011-03-18 2014-04-29 Biotium, Inc. Fluorescent dyes, fluorescent dye kits, and methods of preparing labeled molecules
WO2013036743A1 (en) 2011-09-09 2013-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Imaging agents for imaging protease activity and uses thereof
US20140180073A1 (en) 2012-12-24 2014-06-26 Anticancer, Inc. Portable digital imaging system for fluorescence-guided surgery
KR20160037834A (ko) 2013-03-14 2016-04-06 루미셀, 아이엔씨. 의료 이미징 장치 및 사용 방법
WO2014171899A1 (en) * 2013-04-19 2014-10-23 Agency For Science, Technology And Research Tunable fluorescence using cleavable linkers
CN107406872B (zh) * 2015-01-22 2023-03-28 里兰斯坦福初级大学理事会 用于标记动物组织的化合物、组合物及其应用
EP3601261A4 (en) * 2017-03-30 2021-07-14 The Board of Trustees of the Leland Stanford Junior University CONTRAST AGENTS ACTIVATED BY A PROTEASE FOR IN VIVO IMAGING

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014111600A (ja) 2006-04-28 2014-06-19 Childrens Hospital Medical Center 膜貫通薬物送達システムに適用するためのプロサポシン由来の融合タンパク質又はポリペプチドを含む組成物
JP2010535167A (ja) 2007-08-03 2010-11-18 サノフィ−アベンティス カスパーゼイメージングプローブ
JP2012508233A (ja) 2008-11-07 2012-04-05 チルドレンズ ホスピタル メディカル センター 膜貫通薬物送達システムへの適用のためのサポシンｃ、並びに関連のタンパク質及びペプチドの融合性
WO2014145257A2 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Oligonucleotide Labeling Reagents，AAT Bioquest(R)，2014年，pp. 1-40

Also Published As

Publication number Publication date
EP3247802A1 (en) 2017-11-29
WO2016118910A1 (en) 2016-07-28
JP2018511556A (ja) 2018-04-26
EP3247802B1 (en) 2024-08-28
US20200299327A1 (en) 2020-09-24
CN107406872B (zh) 2023-03-28
KR20180010177A (ko) 2018-01-30
EP3247802A4 (en) 2018-08-22
US10570173B2 (en) 2020-02-25
JP2022044770A (ja) 2022-03-17
US12459972B2 (en) 2025-11-04
US20240025945A1 (en) 2024-01-25
CN107406872A (zh) 2017-11-28
KR102668593B1 (ko) 2024-05-22
US20180002375A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
JP7689753B2 (ja) 活性に基づくプローブの化合物、組成物、および使用方法
JP2022044770A (ja) ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤
JP7720102B2 (ja) 活性ベースのプローブ化合物、組成物、および使用方法
US20240077475A1 (en) Protease-activated contrast agents for in vivo imaging

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220127

R150 Certificate of patent or registration of utility model

Ref document number: 7017410

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250